5 results on '"Wu, Shuhong"'
Search Results
2. Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.
- Author
-
Yan, Xiang, Wang, Li, Zhang, Ran, Pu, Xingxiang, Wu, Shuhong, Yu, Lili, Meraz, Ismail M., Zhang, Xiaoshan, Wang, Jacqueline F., Gibbons, Don L., Mehran, Reza J., Swisher, Stephen G., Roth, Jack A., and Fang, Bingliang
- Subjects
CANCER treatment ,NON-small-cell lung carcinoma ,PROGRAMMED cell death 1 receptors ,IMMUNOTHERAPY - Abstract
Anti-PD-1 and anti-PD-L1 immunotherapy has provided a new therapeutic opportunity for treatment of advanced-stage non-small cell lung cancer (NSCLC). However, overall objective response rates are approximately 15%–25% in all NSCLC patients who receive anti-PD therapy. Therefore, strategies to overcome primary resistance to anti-PD immunotherapy are urgently needed. We hypothesized that the barrier to the success of anti-PD therapy in most NSCLC patients can be overcome by stimulating the lymphocyte infiltration at cancer sites through locoregional virotherapy. To this end, in this study, we determined combination effects of anti-PD immunotherapy and oncolytic adenoviral vector-mediated tumor necrosis factor-α-related apoptosis-inducing ligand (TRAIL) gene therapy (Ad/E1-TRAIL) or adenoviral-mediated TP53 (Ad/CMV-TP53) gene therapy in syngeneic mice bearing subcutaneous tumors derived from M109 lung cancer cells. Both anti–PD-1 and anti–PD-L1 antibodies failed to elicit obvious therapeutic effects in the M109 tumors. Intratumoral administration of Ad/E1-TRAIL or Ad/CMV-TP53 alone suppressed tumor growth in animals preexposed to an adenovector and bearing subcutaneous tumors derived from M109 cells. However, combining either anti–PD-1 or anti–PD-L1 antibody with these two adenoviral vectors elicited the strongest anticancer activity in mice with existing immunity to adenoviral vectors. Dramatically enhanced intratumoral immune response was detected in this group of combination therapy based on infiltrations of CD4+ and CD8+ lymphocytes and macrophages in tumors. Our results demonstrate that resistance to anti–PD-1 immunotherapy in syngeneic mouse lung cancer can be overcome by locoregional virotherapy. [ABSTRACT FROM PUBLISHER]
- Published
- 2018
- Full Text
- View/download PDF
3. Insulin-Like Growth Factor Binding Protein-2 Level Is Increased in Blood of Lung Cancer Patients and Associated with Poor Survival.
- Author
-
Guo, Chengcheng, Lu, Haibo, Gao, Wen, Wang, Li, Lu, Kaihua, Wu, Shuhong, Pataer, Apar, Huang, Maosheng, El-Zein, Randa, Lin, Tongyu, Roth, Jack A., Mehran, Reza, Hofstetter, Wayne, Swisher, Stephen G., Wu, Xifeng, and Fang, Bingliang
- Subjects
INSULIN-like growth factor-binding proteins ,LUNG cancer ,BLOOD testing ,GENE expression ,ENZYME-linked immunosorbent assay ,BIOMARKERS ,HEALTH outcome assessment - Abstract
Background:We recently showed that IGFBP2 is overexpressed in primary lung cancer tissues. This study aims to determine whether IGFBP2 is elevated in blood samples of lung cancer patients and whether its level is associated with clinical outcomes. Methodology/Principal Findings:Plasma IGFBP2 levels were determined blindly by enzyme-linked immunosorbent assay in 80 lung cancer patients and 80 case-matched healthy controls for comparison. We analyzed blood samples for IGFBP2 levels from an additional 84 patients with lung cancer and then tested for associations between blood IGFBP2 levels and clinical parameters in all 164 lung cancer patients. All statistical tests were two-sided and differences with p<0.05 were considered significant. The mean plasma concentration of IGFBP2 in lung cancer patients was significantly higher than that in healthy controls (388.12±261.00 ng/ml vs 219.30±172.84 ng/ml, p<0.001). IGFBP2 was increased in all types of lung cancer, including adenocarcinoma, squamous cell cancer, and small-cell cancer, regardless of patients’ age, sex, or smoking status. IGFBP2 levels were mildly but significantly associated with tumor size and were significantly higher in stage IV than stage I or III disease. A multivariate analysis showed that lung cancer patients whose blood IGFBP2 was higher than 160.9 ng/ml had a poor survival outcome, with a hazard ratio of 8.76 (95% CI 1.12-68.34, p=0.038 after adjustment for tumor size, pathology, and stage). The median survival time for patients with blood IGFBP2 >160.9 ng/ml is 15.1 months; whereas median survival time was 128.2 months for the patients whose blood IGFBP2 was ≤160.9 ng/ml (p =0.0002). Conclusions/Significance:Blood IGFBP2 is significantly increased in lung cancer patients. A high circulating level of IGFBP2 is significantly associated with poor survival, suggesting that blood IGFBP2 levels could be a prognostic biomarker for lung cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells
- Author
-
Liu, Xiaoying, Guo, Wei, Wu, Shuhong, Wang, Li, Wang, Ji, Dai, Bingbing, Kim, Edward S., Heymach, John V., Wang, Michael, Girard, Luc, Minna, John, Roth, Jack A., Swisher, Stephen G., and Fang, Bingliang
- Subjects
- *
LUNG cancer treatment , *ANTINEOPLASTIC agents , *ENZYME inhibitors , *CANCER cell growth , *CELL differentiation , *DISEASE susceptibility - Abstract
Abstract: NSC-743380 is a novel STAT3 inhibitor that suppresses the growth of several NCI-60 cancer cell lines derived from different tissues and induces regression of xenograft tumors in vivo at various doses. To evaluate the antitumor activity of NSC-743380 in lung cancer cells, we analyzed the susceptibility of 50 NSCLC cell lines to this compound using cell viability assay. About 32% (16 of 50) of these cell lines were highly susceptible to this compound, with a 50% inhibitory concentration (IC50) of <1μM. In mechanistic studies, the increased numbers of apoptotic cells as well as increased PARP cleavage showed that cytotoxic effects correlate with apoptosis induction. Treatment with NSC-743380 inhibited transcription factor STAT3 activation and induced ROS production in sensitive human lung cancer cell lines but not in resistant cells. Blocking ROS generation with the antioxidant NDGA dramatically abolished NSC-743380-induced growth suppression and apoptosis, but had minimal effect on NSC-743380-induced STAT3 inhibition, suggesting that STAT3 inhibition is not caused by ROS production. Interestingly, knockdown of STAT3 with use of shSTAT3 induced ROS generation and suppressed tumor cell growth. Moreover, scavenging ROS induced by STAT3 inhibition also diminished antitumor activity of STAT3 inhibition. In vivo administration of NSC-743380 suppressed tumor growth and p-STAT3 in lung tumors. Our results indicate that NSC-743380 is a potent anticancer agent for lung cancer and that its apoptotic effects in lung cancer cells are mediated by induction of ROS through STAT3 inhibition. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
5. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.
- Author
-
Hao, Chuncheng, Wang, Li, Peng, Shaohua, Cao, Mengru, Li, Hongyu, Hu, Jing, Huang, Xiao, Liu, Wei, Zhang, Hui, Wu, Shuhong, Pataer, Apar, Heymach, John V., Eterovic, Agda Karina, Zhang, Qingxiu, Shaw, Kenna R., Chen, Ken, Futreal, Andrew, Wang, Michael, Hofstetter, Wayne, and Mehran, Reza
- Subjects
- *
NON-small-cell lung carcinoma , *GENETIC mutation , *XENOGRAFTS , *LUNG cancer patients , *LUNG cancer treatment , *ANTINEOPLASTIC agents , *EXONS (Genetics) - Abstract
Molecular annotated patient-derived xenograft (PDX) models are useful for the preclinical investigation of anticancer drugs and individualized anticancer therapy. We established 23 PDXs from 88 surgical specimens of lung cancer patients and determined gene mutations in these PDXs and their paired primary tumors by ultradeep exome sequencing on 202 cancer-related genes. The numbers of primary tumors with deleterious mutations in TP53, KRAS, PI3KCA, ALK, STK11, and EGFR were 43.5%, 21.7%, 17.4%, 17.4%, 13.0%, and 8.7%, respectively. Other genes with deleterious mutations in ≥3 (13.0%) primary tumors were MLL3, SETD2, ATM, ARID1A, CRIPAK, HGF, BAI3, EP300, KDR, PDGRRA and RUNX1 . Of 315 mutations detected in the primary tumors, 293 (93%) were also detected in their corresponding PDXs, indicating that PDXs have the capacity to recapitulate the mutations in primary tumors. Nevertheless, a substantial number of mutations had higher allele frequencies in the PDXs than in the primary tumors, or were not detectable in the primary tumor, suggesting the possibility of tumor cell enrichment in PDXs or heterogeneity in the primary tumors. The molecularly annotated PDXs generated from this study could be useful for future translational studies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.